Ampersand Capital Partners

Boston, Massachusettsampersandcapital.com1expert edge

Boston-based growth equity firm founded 1988 with $4B+ AUM focused exclusively on lower to middle-market healthcare and life sciences companies. Invests in lab services, contract manufacturing, pharma services, and specialty pharma with 203 cumulative investments.

Why interesting to a deal team

Operating Partner 2018-2025 (Paul H. Johnson) demonstrates deep PE expertise in healthcare/pharma services sector; potential co-investment partner or competitive insights on platform consolidation strategy and deal flow.

Experts connected to this company

Paul H. JohnsonOperating Partner, 2018 to 2025

Paul H. Johnson

Executive Chairman

Tjoapack

AdvisorSan Antonio

Executive Chairman of Tjoapack and 30-year CDMO operator who sold DPT/Renaissance to Mylan for $950M — brings both operating and PE-diligence lenses to topicals/injectables manufacturing.

Sources

Structured dataPrimary
ampersandcapital.com
Name + firmOther
privateequityinternational.com/institution-profiles/ampersand-capital-partners.html

Strongest evidenceStructured data2 public sourcesHow the grades work